2014 ASCO GU Thursday

San Francisco, CA -GU Cancers Symposium 2014: Charles G. Drake, MD, PhD discusses abstract #2 "Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)" during the General Session 2: Prostate Cancer—Current Role of Immunotherapy in the Clinic at the 2014 Genitourinary Cancers Symposium here today, Thursday January 30, 2014. Over 3,100 physicians, researchers, patient advocates and healthcare professionals from over 50 countries attended the meeting which features the latest research on genitourinary cancer treatment and prevention. Photo by © ASCO/Todd Buchanan 2014 Technical Questions: todd@medmeetingimages.com